Lilly rDNA Glucagon Is Second Approved, Could Beat Novo GlucaGen Launch
Lilly's recombinant DNA-derived glucagon is the second approved by FDA and could become the first to reach the market.
You may also be interested in...
Pharmaceutical blockbusters are more likely to emerge from an R&D program that downplays commercial forecasts, Johnson & Johnson Worldwide Pharmaceuticals Group Chairman Christine Poon suggested
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011